Aspirin in Older Patients: Risk Instead of Benefit?
In this article
The decades-old hypothesis in oncology that “low-dose aspirin protects against cancer” is undergoing a fundamental revision, particularly in the geriatric population. Published in JAMA Oncology on 29 January 2026, the ASPREE-XT results, which include 8.6 years of long-term follow-up data from the ASPREE trial, have shaken one of modern medicine’s established paradigms. The research shows that aspirin’s known anti-inflammatory and antitumor effects are not only ineffective in people aged 70 and older but may also be associated with an unexpected increase in cancer mortality (death rates). By proving that aspirin use in an aging immune system and a changing tumor microenvironment follows a course opposite to the protective mechanisms seen in younger populations, this critical finding declares the end of a “one treatment for every age” approach in oncology and geriatrics.
Study Details and Methodological Strength
ASPREE (Aspirin in Reducing Events in the Elderly) is one of the world’s most comprehensive randomized, double-blind, placebo-controlled clinical trials examining aspirin’s effects in healthy older adults. This updated analysis from 2026 includes the following details:
A Large Participant Cohort
From Australia and the USA, 19114 healthy individuals (aged 70+, or 65+ for African American and Hispanic participants) were included in the study. This number provides data with the greatest statistical power for the older population.
ASPREE-XT Follow-Up
Following the original clinical trial, the ASPREE-XT observational phase brought the total median follow-up to 8.6 years. This long duration is critical for observing cancer development and late effects.
Dose and Protocol
Participants were randomized to receive 100 mg of enteric-coated aspirin or placebo daily. Analyses of cancer incidence, stage, and death rates were conducted meticulously.
ASPREE 2026: Key Clinical Implications
- 1. No Protective Effect: Despite long-term follow-up, cancer incidence did not decrease in the aspirin group.
- 2. Increased Cancer-Specific Mortality: On statistical analysis, cancer-related deaths were higher in the aspirin arm than in the placebo group.
- 3. Age and Biology: The study showed that aspirin’s antitumor mechanisms, such as immune surveillance, function differently in older adults than in younger age groups.
A Strategic Approach by Age Group
Ages 50-69
Status: Low-dose use for cardiovascular risk management and colorectal cancer prevention remains an option that can still be discussed on an individual basis.
Age 70 and Older
Clear Evidence: Starting aspirin solely to prevent cancer is not recommended in healthy older adults; existing use is also questioned if there is no cardiovascular necessity.
Data Analysis: Aspirin vs. Placebo
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.